Monster (MONT) Offers Files For Trademark Protection With USPTO

SAN DIEGO, Feb. 17, 2012 /PRNewswire/ — Monster Offers (OTCBB: MONT), a leading Daily Deal analytics provider and aggregator, today announced it has filed for trademark protection of its service mark as it expands its products and service offerings. This move is largely proprietary since the company has been using the Monster Offers name continuously since 2007.

According to the USPTO, owning a federal trademark on the Principal Register provides several key advantages, including:

• Public notice of your claim of ownership of the mark;
• A legal presumption of your ownership of the mark and your exclusive right to use the mark nationwide on or in connection with the goods/services listed in the registration;
• The ability to bring an action concerning the mark in federal court;
• The use of the U.S. registration as a basis to obtain registration in foreign countries;
• The ability to record the U.S. registration with the U.S. Customs and Border Protection (CBP) Service to prevent importation of infringing foreign goods;
• The right to use the federal registration symbol ®; and
• Listing in the United States Patent and Trademark Office’s online databases

About Monster Offers:

Monster Offers is a leading Daily Deal analytics provider and aggregator collecting daily deals from multiple sites in local communities across the U.S. and Canada. Focused on providing innovation and utility for Daily Deal consumers and providers, the company collects and publishes thousands of daily deals and allows consumers to organize these deals by geography or product categories, or to personalize the results using keyword search. More information can be found by visiting http://www.monsteroffers.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, the risks associated with the management appointment described in this press release, and other risks identified in the filings by Monster Offers (MONT), with the Securities and Exchange Commission. Further information on risks faced by MONT are detailed in the Form 10-K for the year ended December 31, 2010, and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Monster Offers does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:
For Monster Offers
PublicRelations@monsteroffers.com

Improved Cord Blood Processing Research on BioLife Solutions (BLFS) CryoStor® Published in TRANSFUSION

nSales and Socket Mobile (SCKT) Partner to Bring Sales Force Automation to the Apple(R) iPad(R)

NEWARK, CA — (Marketwire) — 02/16/12 — Socket Mobile, Inc. (NASDAQ: SCKT), an innovative provider of mobile productivity solutions, today announced a partnership with nSales, a developer of mobile software for sales force automation. The collaboration enables sales representatives to quickly enter orders, look up account information, and check inventory levels during customer visits using a stylish, easy-to-use solution based on the Apple iPad.

The partnership combines the Socket Bluetooth® Cordless Hand Scanner (CHS) 7Xi, a small and lightweight portable barcode reader that has been certified by Apple for the iPad and other iOS devices, with nVision Mobile sales and CRM software, which nSales developed with the SocketScan 10 Software Development Kit from Socket Mobile. The combined solution enables sales representatives to save time and minimize errors during order entry by eliminating paper forms and leveraging fast, commercial-grade barcode scanning to quickly and accurately enter product numbers.

“Socket Mobile has an excellent reputation as a mobile device manufacturer, and nSales is proud to offer Socket barcode scanners with our nVision Mobile sales and CRM solution to our customers in the clothing, jewelry and gift industries,” said Lasse Styner Rostock, CEO of nSales. “Not only do our customers appreciate Socket barcode scanners for their high quality and ease of use with the Apple iPad, but developers at nSales found the Socket SDK to be well written and well documented, allowing us to add customized barcode scanning support to our software in only a few days.”

“Socket Mobile is pleased to partner with nSales to offer a powerful sales force automation solution based on the Apple iPad,” said Mike Gifford, executive vice president at Socket Mobile. “With applications from experienced developers like nSales and effective hardware peripherals like the Socket CHS barcode scanner, the Apple iPad can be elevated from a consumer device to an indispensible business tool for mobile workers.”

The Socket CHS 7Xi barcode scanner is available with an optional Software Development Kit (SDK). To learn more, please watch this video or visit the SDK webpage.

About nSales
nSales is a developer of mobile software for service technicians, sales representatives and other field workers. For more information, please visit www.nvisionmobile.com or email lasse@nsales.dk.

About Socket Mobile, Inc.
With 20 years of experience in the Automatic Identification and Data Capture market, Socket makes mobile computing and productivity work. The company offers a family of handheld computers and an extensive portfolio of AIDC peripherals designed specifically for business mobility deployments and to enable productivity increases and drive operational efficiencies in healthcare, hospitality and other vertical markets. The company also offers OEM solutions for the mobile device market. Socket is headquartered in Newark, Calif. and can be reached at +1-510-933-3000 or www.socketmobile.com. Follow Socket Mobile on Twitter @socketmobile and subscribe to sockettalk.socketmobile.com, the company’s official blog.

Socket and Bluetooth Cordless Hand Scanner are trademarks or registered trademarks of Socket Mobile. All other trademarks and trade names contained herein may be those of their respective owners.

© 2012, Socket Mobile, Inc. All rights reserved.

Adeona (AEN) Becomes Synthetic Biologics, Inc. (SYN)

Forward Industries (FORD) Signs Global Partnership with Annex Products

India Globalization Capital (IGC) Announces Financial Results for the Quarter Ended December 31, 2011

BETHESDA, MD — (Marketwire) — 02/16/12 — India Globalization Capital, Inc. (NYSE Amex: IGC)

• Completes acquisition of Ironman.
• Strengthens balance sheet.
• Expands capacity at beneficiation plant by 50%.
• Projects a swing to profitability in Fiscal 2013.

India Globalization Capital, Inc. (NYSE Amex: IGC), a company competing in the burgeoning Indian and Chinese materials and infrastructure industries, announced financial results for the Third quarter of Fiscal Year 2012 that Ended December 31, 2011.

Ram Mukunda CEO of IGC said, “This quarter the team has been focused on completing the acquisition of Ironman. In addition we are in the process of expanding capacity at the beneficiation plant by 50%. We also acquired a mining property, which at $127 per ton has an estimated $225 million of iron ore reserves. This brings our total projected reserves of iron ore and rock aggregate to about $590 million. We expect the new plant to be operational by the end of March and in time for the beginning of our fiscal year starting April 1, 2012. In addition we are in the process of increasing synergies between our Indian operations and Chinese operations. We have a unique strategy of shipping low-grade ore to our plants and processing it to a higher grade before selling it to our customers. This allows us to take advantage of the price arbitrage between low grade and high grade ore.”

The acquisition of Ironman closed on December 31, 2011 and therefore our consolidated financials include a consolidation of the balance sheet but not the income statement of Ironman. The profit and loss consolidation will commence on January 1, 2012 and will be included in the next quarter ending March 31, 2012.

Total revenue for IGC was $987 thousand for the three months ended December 31, 2011, as compared to $484 thousand for the three months ended December 31, 2010. As there is still a ban on iron ore exports from Karnataka, we increased domestic trading. The revenue reported for December 31, 2011 does not include an additional $879 thousand that was generated by our rock aggregate joint venture, because we own 49% of the joint venture. The revenue in the Joint Venture was up by 37% from $642 thousand in the previous quarter ended September 30, 2011. We continue to see strong demand for both ore and aggregate in our local markets in India.

The selling general and administrative expenses (SG&A) were $969 thousand for the three months ended December 31, 2011 compared to $1,054 thousand for the three months ended December 31, 2010. In this quarter, we included $400 thousand of one-time charges related to the acquisition of Ironman.

Consolidated net loss for the three months ended December 31, 2011 was $1.914 million compared to a consolidated net loss of $1.762 million for the three months ended December 31, 2010. In this quarter the net loss includes a one-time charge of $400 thousand for the acquisition of Ironman and $818 thousand in a foreign exchange translation loss. Over the quarter, the Indian rupee weakened drastically against the US dollar.

The Company reported a GAAP net loss of ($0.09) per basic share versus a GAAP net loss of ($0.12) per basic share for the three months ended December 31, 2010. The non-GAAP pro forma EPS inclusive of all one-time charges and inclusive of Ironman was a net profit of $0.04 per basic share.

As of December 31, 2011, the Company’s stockholders’ equity was approximately $14,079,469 compared to $7,292,859 for the period ended March 31, 2011. The increase was from the acquisition of Ironman. The Company reported total assets of approximately $35.1 million on December 31, 2011 versus approximately $18.16 million on March 31, 2011. The increase was from the consolidation of the Ironman balance sheet. The Company reported cash, cash equivalents, and restricted cash used as deposits of approximately $4.62 million. The Company reported notes payable and short-term borrowings of $4.25 million as of December 31, 2011 versus $4.82 million as of March 31, 2011. The Company repaid $571 thousand in the nine-month period.

             INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS

                                       All amounts in USD except share data

                                                           As of
                                               ----------------------------
                                                December 31,    March 31,
                                                    2011           2011
                                                (unaudited)     (audited)
                                               -------------  -------------
                    ASSETS
Current assets:
Cash and cash equivalents                      $   4,444,972  $   1,583,284
Accounts receivable, net of allowances             5,971,786      3,312,051
Inventories                                          767,432        133,539
Advance taxes                                         41,452         41,452
Dues from related parties                            239,947              -
Prepaid expenses and other current assets          3,097,845      1,474,838
                                               -------------  -------------
Total current assets                           $  14,563,434  $   6,545,164
                                               -------------  -------------
Goodwill                                             952,836        410,454
Property, plant and equipment, net                 8,021,606      1,231,761
Intangible assets                                  3,880,957             -
Investments in affiliates                          6,303,315      6,428,800
Investments-others                                   766,060        877,863
Deferred income taxes                                180,929              -
Restricted cash                                      182,619      1,919,404
Other non-current assets                             246,863        748,623
                                               -------------  -------------
Total assets                                   $  35,098,619  $  18,162,069
                                               =============  =============

     LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term borrowings                          $     764,871  $     901,343
Trade payables                                       998,560      1,311,963
Accrued expenses                                   1,316,012        349,149
Notes payable                                      3,485,254      3,920,000
Taxes payable                                      3,085,107              -
Other taxes payable                                1,764,816              -
Dues to related parties                              310,643              -
Deferred tax liabilities                             135,980
Other current liabilities                          1,091,603         94,892
                                               -------------  -------------
Total current liabilities                      $  12,952,846  $   6,577,347
                                               -------------  -------------
Deferred income taxes                                713,897              -
Other non-current liabilities                      4,270,023      1,209,479
                                               -------------  -------------
Total liabilities                              $  17,936,766  $   7,786,826
                                               -------------  -------------

Shares potentially subject to rescission
 rights (4,868,590 shares issued and
 outstanding)                                      3,082,384      3,082,384

Stockholders' equity:
  Common stock - $.0001 par value; 150,000,000
   shares authorized; 47,591,843 issued and
   outstanding as of December 31, 2011 and
   14,890,181 issued and outstanding as of
   March 31, 2011                                      4,760          1,490
  Additional paid-in capital                      48,887,101     38,860,319
  Accumulated other comprehensive income          (2,625,115)    (2,502,596)
  Retained earnings (Deficit)                    (33,252,738)   (29,692,907)
                                               -------------  -------------
    Total equity attributable to the parent    $  13,014,008  $   6,666,306
  Non-controlling interest                         1,065,461        626,553
                                               -------------  -------------
    Total stockholders' equity                 $  14,079,469  $   7,292,859
                                               -------------  -------------
Total liabilities and stockholders' equity     $  35,098,619  $  18,162,069
                                               =============  =============

   The accompanying notes should be read in connection with the financial
                                 statements.

             INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                                (Unaudited)

                                       All amounts in USD except share data

                            Three months ended         Nine months ended
                               December 31,              December 31,
                         ------------------------  ------------------------
                             2011         2010         2011         2010
                         -----------  -----------  -----------  -----------

  Revenues               $   986,799  $   484,106  $ 2,959,167  $ 3,294,103
  Cost of revenues
   (excluding
   depreciation and
   amortization)          (1,024,817)    (457,379)  (2,902,650)  (3,053,512)
  Selling, general and
   administrative
   expenses                 (968,890)  (1,054,894)  (2,354,405)  (2,399,503)
  Depreciation               (42,360)    (461,627)    (169,225)    (659,002)
                         -----------  -----------  -----------  -----------
Operating income (loss)  $(1,049,268) $(1,489,794) $(2,467,113) $(2,817,914)
  Interest expense          (174,353)    (307,630)    (624,086)    (718,339)
  Amortization of debt
   discount                        -            -            -     (356,436)
  Interest income             59,629       40,657      186,061      170,438
  Other income, net         (716,364)     (25,914)    (706,440)      34,558
Income before income
 taxes and minority
 interest attributable
 to non-controlling
 interest                $(1,880,356) $(1,782,681) $(3,611,578) $(3,687,693)
  Earnings in Income
   from Affiliates           (33,588)           -       28,463            -
  Income taxes benefit/
   (expense)                       -       20,212            -      475,226
                         -----------  -----------  -----------  -----------
Net income/(loss)        $(1,913,944) $(1,762,469) $(3,583,115) $(3,212,467)
  Non-controlling
   interests in earnings
   of subsidiaries            12,569       13,451       23,284       16,014
                         -----------  -----------  -----------  -----------
Net income / (loss)
 attributable to common
 stockholders            $(1,901,375) $(1,749,018) $(3,559,831) $(3,196,453)
                         ===========  ===========  ===========  ===========
Earnings/(loss) per
 share attributable to
 common stockholders:
  Basic and diluted      $     (0.09) $     (0.12) $     (0.17) $     (0.23)
Weighted-average number
 of shares used in
 computing earnings per
 share amounts:
  Basic and diluted       21,301,092   14,750,483   20,880,604   13,814,634

   The accompanying notes should be read in connection with the financial
                                 statements.

About IGC

Based in Bethesda, Maryland, India Globalization Capital (IGC) is a materials and construction company operating in India and China. We operate beneficiation plants in China and rock aggregate sites in India. We supply materials to the burgeoning infrastructure industries in India and China. For more information about IGC, please visit IGC’s website at www.indiaglobalcap.com. For more information on our Chinese operations, including a video on the iron ore beneficiation process, please visit the Web site at www.hfironman.net

Forward-looking Statements:

Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential,” “proposed,” or “continue” or the negative of those terms. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of IGC concerning PRC Ironman with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond IGC’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, our competitive environment, infrastructure demands, iron ore availability and governmental, political, economic, legal and social conditions in China.

Factors that could cause actual results to differ, relate to the (i) ability of IGC to successfully execute on contracts and business plans, (ii) ability to raise capital and the structure of such capital including the exercise of warrants, (iii) exchange rate changes between the U.S. dollar, the Chinese RMB and the Indian rupee, (iv) weather conditions in China and India, (v) uncertainties with respect to the People’s Republic of China’s legal and regulatory environment, and (vi) ability of the Company to access ports on the coasts of India. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC’s amended Annual Report on Form 10-K for the year ended March 31, 2011 and Schedule 14A filed on December 9, 2011 with the Securities and Exchange Commission.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact Information
Investor Relations
John Selvaraj
301-983-0998

Recon (RCON) Reports Second Quarter 2012 Financial Results

BioDelivery Sciences (BDSI) Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals

RALEIGH, N.C. and CHADDS FORD, Pa., Feb. 16, 2012 /PRNewswire/ — BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance of BDSI’s patent application (No. 13/184306) that, once formally granted, will extend the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone from 2020 to 2027.

A Notice of Allowance is issued when the USPTO has determined to grant a patent. Once the issue fee is paid, the final granting of the patent takes place, typically within a few months.

As a part of BDSI’s recently signed BEMA Buprenorphine licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP), BDSI is entitled to a milestone payment in the amount of $15 million upon the final granting of this patent.

“We are very pleased by the allowance of this patent application by the USPTO, that will not only provide non-dilutive capital to BDSI in the next couple months, but importantly extends the period of exclusivity, and thus the potential for a longer royalty stream, for BEMA Buprenorphine in its use for treating chronic pain following FDA approval and commercial launch,” stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI. “It is an added benefit that this patent upon granting will afford similar protection to BEMA Buprenorphine/Naloxone for the treatment of opioid dependence.”

“Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain,” said Dr. Ivan Gergel, M.D., executive vice president, R&D and chief scientific officer, Endo Pharmaceuticals. “And the allowance of the patent application is an exciting step in continuing Endo’s tradition of novel product development in the field of pain management.”

BDSI expects the final granting of the patent and associated payment of the $15 million milestone within the next few months.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI’s second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence. BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Pharmaceuticals. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron). BDSI’s headquarters is located in Raleigh, North Carolina. For more information, visit www.bdsi.com.

BDSI^® and BEMA^® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS^® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

About Endo

Endo Pharmaceuticals Holdings is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals Holdings and its businesses American Medical Systems, HealthTronics and Qualitest Pharmaceuticals, please visit http://www.endo.com/.

BDSI Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results (i) relating to the Company’s commercial partnership with Endo Pharmaceuticals (including the milestone payment due upon issuance of the patent described herein), (ii) of regulatory review of BEMA Buprenorphine and the payment of related milestone payments to the Company or (iii) sales results for BEMA Buprenorphine and resulting potential royalty payments to the Company) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.

Endo Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo Pharmaceuticals

Adept Technology (ADEP) Receives $1.4 Million Order From International Equipment OEM

PLEASANTON, Calif., Feb. 14, 2012 (GLOBE NEWSWIRE) — Adept Technology, Inc. (Nasdaq:ADEP), a leading provider of intelligent robots and autonomous mobile solutions, today announced it has received a $1.4 million order for high-precision robots from a major international manufacturer of sophisticated automation equipment for use in the consumer electronics and information technology industries. The order is expected to be fulfilled and recognized as revenue over the next two quarters. The company selected Adept as its automation partner to provide advanced robotic systems to be integrated into their process equipment as part of a program by their end-user manufacturer for increasing production capacities.

“This order is a continued validation of our partnerships and business strategy in Asia,” said Hai Chang, managing director of Asia operations for Adept Technology. “Adept continues to set the standard in the consumer electronics and information technology industry with our best-in-class high-precision mechanisms and controls technology.”

The order for Adept Python™ linear modules will be used in high-throughput, high-precision material handling applications. Adept Python robots have proven over the years to deliver consistently reliable performance and yields for our end-user customers. Additionally, the Adept SmartController CX controller and distributed controls platform allow the customer to fully leverage and benefit from Adept’s inherent multi-robot support capabilities, allowing up to 15 individually-configured robots to be commanded through one controller. Adept’s Python linear modules were also selected for their industry-leading cleanliness in controlled environments, with available options that are capable of meeting Fed 209E class 1 cleanroom standards at high motion speeds.

About Adept Technology, Inc.

Adept is a global, leading provider of intelligent robots and autonomous mobile solutions and services that enable customers to achieve precision, speed, quality and productivity in their assembly, handling, packaging, testing, and logistical processes. With a comprehensive portfolio of high-performance motion controllers, application development software, vision-guidance technology and high-reliability robot mechanisms with autonomous capabilities, Adept provides specialized, cost-effective robotics systems and services to high-growth markets including Packaging, Medical, Disk Drive/Electronics, and Solar; as well as to traditional industrial markets including machine tool automation and automotive components. More information is available at http://www.adept.com.

The Adept Technology logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5387

Forward-Looking Statements

This press release contains forward-looking statements including, without limitation, statements about our expectations for revenues and cash flow and opportunities in our core markets and potential new markets. Such statements are based on current expectations and projections about the Company’s business. These statements are not guarantees of future performance and involve numerous risks and uncertainties that are difficult to predict. The Company’s actual results could differ materially from those expressed in forward-looking statements for a variety of reasons. For a discussion of these risk factors relating to Adept’s business, see Adept’s SEC filings, including the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2011, which includes the discussion in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Risk Factors.

CONTACT: Press and Industry Analysts:
         Lauren Bucher
         Marketing
         925.245.3533 (voice)
         925.245.3555 (fax)
         lauren.bucher@adept.com

         Financial Analysts:
         Lisa Cummins
         Chief Financial Officer
         925.245.3413 (voice)
         925.245.3510 (fax)
         investor.relations@adept.com

SPAR Group (SGRP) Announces 2011 Fiscal Year End Revenue Guidance of $72 Million

TARRYTOWN, NY — (Marketwire) — 02/14/12 — SPAR Group, Inc. (NASDAQ: SGRP) (the “Company” or “SPAR Group”), a leading supplier of retail merchandising and other marketing services throughout the United States and internationally, today announced revenue guidance of $72 Million for the fiscal year 2011. This would represent an increase in revenue of $9 million or 14%, compared to the same period in 2010.

“Management is pleased with the Company’s anticipated double digit growth for the 2011 fiscal year,” stated Gary Raymond, Chief Executive Officer of SPAR Group. “We are confident that SPAR Group will grow even more aggressively throughout 2012 due to the increased capabilities of our international division and our current pipeline of new contracts. The international subsidiaries we established in 2011 are expected to significantly augment our business and increase revenue starting in the first quarter of 2012. Our strategy of identifying opportunities that will deepen our product and service offerings globally has been a tremendous success and we expect to secure additional profitable acquisitions that will have a positive effect on the Company’s revenue going forward. Our main focus remains on the effective integration of our endeavors in China, Mexico, Turkey, and India, while increasing sales and improving overall profitability.”

The Company’s anticipated revenue improvement is primarily attributable to continued growth both domestically and internationally through its new subsidiaries established in Mexico and Turkey as well as significant incremental revenue growth in a majority of the international markets, most notably in South Africa and Canada. SPAR Group’s efforts to expand its domestic and international market shares are expected to increase profitability well into 2012. SPAR Group will continue to review additional acquisition and growth opportunities that could be accretive to 2012 forecasted earnings.

About SPAR Group
SPAR Group, Inc. is a diversified international merchandising and marketing services company and provides a broad array of services worldwide to help companies improve their sales, operating efficiency and profits at retail locations. The Company provides merchandising and other marketing services to manufacturers, distributors and retailers worldwide, primarily in mass merchandisers, office supply, grocery and drug store chains, independent, convenience and electronics stores, as well as providing furniture and other product assembly services, in-store events, radio frequency identification (“RFID”) and related technology services and marketing research. The Company has supplied these project and product services in the United States since certain of its predecessors were formed in 1979 and internationally since the Company acquired its first international subsidiary in Japan in May of 2001. Product services include product additions; placement, reordering, replenishment, labeling, evaluation and deletions, and project services include seasonal and special product promotions, product recalls and complete setups of departments and stores. The Company operates throughout the United States and internationally in 9 of the most populated countries, including China and India. For more information, visit the SPAR Group’s Web site at http://www.sparinc.com/.

Certain statements in this news release and such conference call are forward-looking, including (without limitation) growing revenues and profits through organic growth and acquisitions, attracting new business that will increase SPAR Group’s revenues, continuing to maintain costs and consummating any transactions. Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company’s control. The Company’s actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of SPAR Group’s selling and marketing functions, continued customer satisfaction and contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, the success of its international efforts, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions. Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends are discussed in SPAR Group’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings made with the Securities and Exchange Commission from time to time. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Contact:

James R. Segreto
Chief Financial Officer
SPAR Group, Inc.
(914) 332-4100

Investors:
Alan Sheinwald
Alliance Advisors, LLC
(212) 398-3486

Chris Camarra
Alliance Advisors, LLC
(212) 398-3487

Innodata (INOD) Reports Fourth Quarter and Fiscal Year 2011 Results

INNODATA ISOGEN, INC. (NASDAQ: INOD) today reported results for the fourth quarter and the 12 months ended December 31, 2011.

• Total revenue was a record $23.7 million in the fourth quarter of 2011, a sequential increase of 23% from $19.2 million in the third quarter of 2011, and a 59% increase from $14.9 million in the fourth quarter of 2010. The increase is primarily attributable to higher revenue from eBook-related services that the Company performs for one of its larger clients and to revenue from analytics services that the Company performs for a major accounting firm.
• Net income for the fourth quarter of 2011 was $2.3 million, or $0.09 per diluted share, compared to net income of $1.4 million, or $0.06 per diluted share, in the third quarter of 2011, and net income of $1.2 million, or $0.05 per diluted share, in the fourth quarter of 2010. The increase in net income is primarily attributable to higher revenue and to an increase in gross margins from 33% in the third quarter of 2011 and 22% in the fourth quarter of 2010 to 36% in the fourth quarter of 2011.
• For the 12 months ended December 31, 2011, total revenue was $73.9 million, a 20% increase from $61.5 million in 2010. Net earnings improved significantly, from a net loss of $0.7 million, or ($0.03) per diluted share, in 2010, to net earnings of $4.5 million, or $0.18 per diluted share, in 2011. The growth in net earnings is primarily attributable to higher revenue and to an increase in gross margins from 23% in 2010 to 32% in 2011.
• Cash and cash equivalents and short-term investments totaled $17.2 million as of December 31, 2011, a decline of $7.0 million from $24.2 million as of September 30, 2011. The reduction is primarily on account of an $8.8 million increase in accounts receivable from $12.9 million as of September 30, 2011 to $21.7 million as of December 31, 2011 and approximately $2.5 million in investments made during the quarter for establishing two new delivery centers in Asia, and continuing investment in the Company’s recently-launched Innodata Advanced Data Solutions (IADS) segment. A significant portion of the increase in accounts receivable as of December 31, 2011 was from one of our large customers because of a process delay.

“In 2011, we succeeded at growing revenue by 20% and turning a 2010 pre-tax loss of $1.2 million to 2011 pre-tax earnings of $5.3 million, all the while making an investment of $2.7 million in operating expenses and $2 million in capital expenditures in our IADS division,” stated Jack Abuhoff, the Company’s Chairman and CEO. “Our IADS investment has enabled us to build a platform and service capability to provide high quality advanced data analytics to healthcare, financial, and insurance sectors for risk management and related business operations. We expect that IADS will begin contributing to revenue during the first half of 2012.”

Abuhoff concluded, “Our business in 2012 is off to a good start. We’re anticipating revenue for the first quarter of 2012 to be approximately $21.0 million.”

Timing of Conference Call with Q&A

Innodata will conduct an earnings conference call, including a question and answer period, at 11:00 AM eastern time today. You can participate in this call by dialing the following call-in numbers:

The call-in numbers for the conference call are:

1-800-723-6575 (Domestic)

1-785-830-1997 (International)

1-888-203-1112 (Domestic Replay)

1-719-457-0820 (International Replay)

Pass code on both: 7914822

Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of www.innodata.com. Please note that the Webcast feature will be in listen-only mode.

Call-in or Webcast replay will be available for 30 days following the conference call.

Innodata (NASDAQ: INOD) is a leading provider of business process, technology and consulting services, as well as products and solutions, that help our valued clients create, manage, use and distribute digital information. Propelled by a culture of quality, service and innovation, we have developed a client base that includes many of the world’s preeminent media, publishing and information services companies, as well as leading enterprises in information-intensive industries such as aerospace, defense, financial services, government, healthcare, high technology, insurance, intelligence, manufacturing and law.

Recent honors include EContent Magazine’s EContent 100, KMWorld Magazine’s 100 Companies That Matter in Knowledge Management, the International Association of Outsourcing Professionals’ (IAOP) Global Outsourcing Top 100, D&B India’s Leading ITeS and BPO Companies and the Black Book of Outsourcing’s Top List of Leading Outsourcing Providers to the Printing and Publishing Business.

Headquartered in the New York metro area, Innodata has offices and operations in the United States, the United Kingdom, Israel, India, Sri Lanka, and the Philippines.

This release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The words “project,” “head start,” “believe,” “expect,” “should,” “anticipate,” “indicate,” “point to,” “forecast,” “likely”, “optimistic” and other similar expressions generally identify forward-looking statements, which speak only as of their dates.

These forward-looking statements are based largely on our current expectations, and are subject to a number of risks and uncertainties, including without limitation, that our Innodata Advanced Data Solutions segment has not reported any revenues to date and is subject to the risks and uncertainties of early-stage companies; the primarily at-will nature of the contracts between our Content Services segment and its customers and the ability of customers to reduce, delay or cancel projects; continuing Content Services revenue concentration in a limited number of customers; continuing Content Services reliance on project-based work; inability to replace projects that are completed, cancelled or reduced; depressed market conditions; changes in external market factors; the ability and willingness of our customers and prospective customers to execute business plans which give rise to requirements for digital content and professional services in knowledge processing; difficulty in integrating and deriving synergies from acquisitions, joint venture and strategic investments; potential undiscovered liabilities of companies that we acquire; changes in our business or growth strategy; the emergence of new or growing competitors; various other competitive and technological factors; and other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.

Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this release will occur.

FONAR (FONR) Reports 33% Increase in Net Income to $1.8 Million for 2nd Quarter of Fiscal Year 2012

MELVILLE, NY — (Marketwire) — 02/14/12 — FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported today its financial results for the second quarter of fiscal year 2012. For the three months ended December 31, 2011, net income increased 33% to $1.8 million, income from operations increased 31% to $1.9 million while total revenues increased 16% to $9.3 million, as compared to the corresponding fiscal quarter one year earlier.

Results from the Second Quarter Fiscal 2012 Financial Statement:

The basic income per common share increased 56% to $0.50 for the six months ended December 31, 2011 as compared to $0.32 for the same period one year earlier. For the quarter ended December 31, 2011 and 2010, the basic net income per common share was $0.25.

In addition, the diluted income per common share increased 58% to $0.49 for the six months ended December 31, 2011 as compared to $0.31 for the same period one year earlier. For the quarter ended December 31, 2011 and 2010, the diluted net income per common share was $0.24.

Net income for the six month period ended December 31, 2011 rose 105% to $3.6 million as compared to $1.7 million for the six month period ended December 31, 2010. For the quarter ended December 31, 2011, net income climbed 33% to $1.8 million as compared to $1.4 million for the quarter ended December 31, 2010.

Income from operations for the six month period ended December 31, 2011 rose 95% to $3.7 million as compared to $1.9 million for the six month period ended December 31, 2010. For the quarter ended December 31, 2011, income from operations climbed 31% to $1.9 million as compared to $1.4 million for the quarter ended December 31, 2010.

Total revenues for the six month period ended December 31, 2011 rose 13% to $18.9 million as compared to $16.7 million for the six month period ended December 31, 2010. For the quarter ended December 31, 2011, total revenue climbed 16% to $9.3 million as compared to $8.0 million for the quarter ended December 31, 2010.

Total operating costs and expenses increased 3% to $15.3 million for the six months ended December 31, 2011 from $14.8 million for the six months ended December 31, 2010. For the quarter ended December 31, 2011, total operating costs and expenses increased 13% to $7.4 million as compared to $6.6 million for the quarter ended December 31, 2011.

Revenues from product sales were $1.6 million for the fiscal quarter ended December 31, 2011 as compared to $1.8 million for the corresponding quarter ended December 31, 2010. Revenues from service and repair fees were $2.8 million for the fiscal quarter ended December 31, 2011 as compared to $2.7 million for the fiscal quarter ended December 31, 2010.

Revenues from the management and other fees segment (management of the FONAR UPRIGHT® Multi-Position™ MRI diagnostic imaging centers segment) increased 39% to $4.9 million for the fiscal quarter ended December 31, 2011, from $3.5 million for the fiscal quarter ended December 31, 2010.

As of December 31, 2011 total current assets were $25.1 million and total current liabilities were $21.9 million. Total assets were $33.5 million and total liabilities were $24.3 million. Total long-term liabilities were $2.4 million. Total stockholders’ equity was $9.2 million. Total cash and cash equivalents and marketable securities were $9.9 million.

Significant Highlights during the October – December Quarter:

On October 5, 2011, the Company reported a diagnostic breakthrough in the understanding of the genesis of multiple sclerosis (MS) based on observations made possible by the company’s unique FONAR UPRIGHT® Multi-Position™ MRI. The press release indicated that the cause of multiple sclerosis may be biomechanical and related to earlier trauma to the neck, which can result in the obstruction of the flow of cerebrospinal fluid (CSF), which is produced and stored in the central anatomic structures of the brain known as the ventricles. Since the ventricles produce a large volume of CSF each day (500 cc), an obstruction can result in a build-up of pressure within the ventricles, resulting in leakage of the CSF into the surrounding brain tissue. This leakage could be responsible for generating the brain lesions of multiple sclerosis.

The research was published in the journal Physiological Chemistry and Physics and Medical NMR (Sept. 20, 2011, 41: 1-17), titled “The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis.” It was co-authored by FONAR MRI researchers Raymond V. Damadian, M.D., president and chairman of FONAR and FONAR scientist David Chu, PhD. The complete study can be viewed at www.fonar.com/pdf/PCP41_damadian.pdf.

Dr. Damadian said, “We used the UPRIGHT® Multi-Position™ MRI to view the flow of cerebrospinal fluid in and out of the brain with the patients scanned Upright and scanned lying down. The UPRIGHT® MRI also revealed that these obstructions were the result of structural deformities of the cervical spine, induced by trauma earlier in life. The findings are based on viewing the real-time flow of cerebrospinal fluid in a series of eight randomly chosen patients with multiple sclerosis. These invaluable dual observations have only been possible since the invention by FONAR of an MRI capable of imaging the patient Upright.” For more information visit: www.fonar.com.

On October 4, 2011, Dr. Damadian announced the study at a Radiology Department Grand Rounds at the University of California San Diego Medical Center. William G. Bradley, Jr., M.D., Ph.D., F.A.C.R., Chairman of the Department of Radiology, and a Professor of Radiology at UCSD School of Medicine, introduced Dr. Damadian to his colleagues at grand rounds. Dr. Bradley said, “Dr. Damadian has shown that 8 patients with MS had degenerative changes in their cervical spines which impinged on the spinal canal and limited the pulsatile, to-and-fro flow of cervical CSF over the cardiac cycle, as demonstrated on UPRIGHT® MRI. His hypothesis that increased resistance to outflow of CSF is linked to the etiology of MS has some similarities to Dr. P. Zamboni’s hypothesis that MS is due to the impeded outflow of venous blood from the brain due to dural sinus stenoses. In both theories, increased resistance to outflow of either CSF or venous blood would be expected to modify the intracranial pressure wave over the cardiac cycle. While both theories need to be further tested with larger controlled studies, it is intriguing that they seem to invoke similar pathologic changes. Whether these changes are etiologic in all cases of MS remains to be tested.”

On November 2, 2011, FONAR reported on a 41-year-old female patient with MS that had been one of the eight patients in the original study. The FONAR UPRIGHT® MRI had found cervical malrotations at the cranio-cervical junction and alterations of CSF flow dynamics which gave rise to CSF fluid leakages into surrounding brain tissue. The CSF leakages visualized were directly connected to the MS lesions visualized on the UPRIGHT® MRI. Dr. Damadian stated, “These new observations have uncovered biomechanical barriers that appear to lead to multiple sclerosis. It is significant that these barriers may be therapeutically addressable.”

The MS patient was treated by Dr. Scott Rosa, with a proprietary protocol using an Atlas Orthogonal (AO) instrument and the FONAR UPRIGHT® Multi-Position™ MRI. The patient has experienced a significant reduction in symptoms which correlate directly to 28.6% reduction of her CSF pressure on post MRI evaluation. At this time the patient continues to be free of MS symptoms as well as vertigo and vomiting on recumbency. The patient’s care continues being administered by Dr. Rosa.

On November 30, 2011, the Company reported a sale of its UPRIGHT® Multi-Position™ MRI to a radiology practice in the western USA. This becomes the 29th state to have a customer purchase the FONAR UPRIGHT® MRI. The FONAR UPRIGHT® Multi-Position™ MRI has also been sold to Puerto Rico and has been installed in eleven other nations around the world.

The board certified radiologist purchasing the FONAR UPRIGHT® Multi-Position™ MRI for his practice said he was buying the scanner in order to meet the expressed needs of his sending physicians, principally neurosurgeons and orthopedic surgeons. They are eager, he said, to achieve the best possible surgical outcomes for their spine surgery patients. Failure to see the full picture could result in the administration of a wrong or insufficient surgical procedure. They consider imaging the spine fully loaded with its normal weight, and in all the upright positions that the spine normally occupies, fundamental to a good surgical outcome for the patient.

About FONAR

FONAR (NASDAQ: FONR), Melville, NY, The Inventor of MR Scanning™, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world’s first commercial MRI in 1980, and went public in 1981. Since its inception, nearly 300 recumbent-OPEN MRIs and 150 UPRIGHT® Multi-Position™ MRI scanners have been installed worldwide. FONAR’s stellar product is the UPRIGHT® MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often sees the patient’s problem that other scanners cannot because they are lie-down only. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, “If the patient is claustrophobic in this scanner, they’ll be claustrophobic in my parking lot.” Approximately 85% of patients are scanned sitting while they watch a 42″ flat screen TV. FONAR is headquartered on Long Island, New York.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

                                      #

                     FONAR CORPORATION AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                               (000's OMITTED)

                                   ASSETS

                                                  December 31,    June 30,
                                                      2011          2011
Current Assets:                                   (UNAUDITED)
                                                 ------------- -------------
Cash and cash equivalents                        $       9,911 $       9,251

Marketable securities                                       30            33

Accounts receivable - net                                4,823         5,264

Accounts receivable - related party                         60             -

Management and other fees receivable - net               3,635         3,309

Management and other fees receivable - related
 medical practices - net                                 1,307         1,669

Costs and estimated earnings in excess of
 billings on uncompleted contracts                       1,152           169

Inventories                                              3,806         2,400

Current portion of notes receivable - net                  115           114

Prepaid expenses and other current assets                  270           352
                                                 ------------- -------------

Total Current Assets                                    25,109        22,561
                                                 ------------- -------------

Property and equipment - net                             3,374         3,769

Notes receivable                                           315           359

Other intangible assets - net                            4,120         4,318

Other assets                                               535           574
                                                 ------------- -------------

Total Assets                                     $      33,453 $      31,581
                                                 ============= =============

                     FONAR CORPORATION AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                               (000's OMITTED)

                    LIABILITIES AND STOCKHOLDERS' EQUITY

                                                  December 31,    June 30,
                                                      2011          2011
                                                  (UNAUDITED)
                                                 ------------- -------------
Current Liabilities:

  Current portion of long-term debt and capital
   Leases                                        $       1,636 $       2,026
  Accounts payable                                       1,959         2,187
  Other current liabilities                              8,956         8,236
  Unearned revenue on service contracts                  5,275         5,762
  Unearned revenue on service contracts -
   related Parties                                          55             -
  Customer advances                                      3,303         4,846
  Billings in excess of costs and estimated
   earnings on uncompleted contracts                       736             4
  Income tax payable                                         -            75
                                                 ------------- -------------
    Total Current Liabilities                           21,920        23,136

Long-Term Liabilities:
  Accounts payable                                         141           102
  Due to related medical practices                         229           228
  Long-term debt and capital leases, less
   current Portion                                       1,490         1,746
  Other liabilities                                        494           502
                                                 ------------- -------------

    Total Long-Term Liabilities                          2,354         2,578
                                                 ------------- -------------

    Total Liabilities                                   24,274        25,714
                                                 ------------- -------------

                     FONAR CORPORATION AND SUBSIDIARIES
                   CONDENSED CONSOLIDATED BALANCE SHEETS
                              (000's OMITTED)

              LIABILITIES AND STOCKHOLDERS' EQUITY (Continued)

                                                December 31,     June 30,
                                                    2011           2011
                                                (UNAUDITED)
                                               -------------  -------------

STOCKHOLDERS' EQUITY:
Class A non-voting preferred stock $.0001 par
 value; 453,000 shares authorized at December
 31, 2011 and June 30, 2011, 313,451 issued
 and outstanding at December 31, 2011 and June
 30, 2011                                                  -              -

Preferred stock $.001 par value; 567,000
 shares authorized at December 31, 2011 and
 June 30, 2011, issued and outstanding - none              -              -

Common Stock $.0001 par value; 8,500,000
 shares authorized at December 31, 2011 and
 June 30, 2011, 5,774,371 and 5,636,571 issued
 at December 31, 2011 and June 30, 2011,
 respectively; 5,762,728 and 5,624,928
 outstanding at December 31, 2011 and June 30,
 2011, respectively                                        1              1

Class B Common Stock (10 votes per share) $
 .0001 par value; 227,000 shares authorized at
 December 31, 2011 and June 30, 2011, 158
 issued and outstanding at December 31, 2011
 and June 30, 2011                                         -              -

Class C Common Stock (25 votes per share)
 $.0001 par value; 567,000 shares authorized
 at December 31, 2011 and June 30, 2011,
 382,513 issued and outstanding at December
 31, 2011 and June 30, 2011                                -              -

Paid-in capital in excess of par value               173,729        173,476
Accumulated other comprehensive loss                     (20)           (16)
Accumulated deficit                                 (171,061)      (174,110)
Notes receivable from employee stockholders              (74)          (115)
Treasury stock, at cost - 11,643 shares of
 common stock at December 31, 2011 and June
 30, 2011                                               (675)          (675)
Non controlling interests                              7,279          7,306
                                               -------------  -------------

Total Stockholders' Equity                             9,179          5,867
                                               -------------  -------------

Total Liabilities and Stockholders' Equity     $      33,453  $      31,581
                                               =============  =============

                     FONAR CORPORATION AND SUBSIDIARIES
          CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
                   (000's OMITTED, except per share data)

                                                FOR THE THREE MONTHS ENDED
                                                       DECEMBER 31,
                                               ----------------------------
REVENUES                                            2011           2010
                                               -------------  -------------
  Product sales - net                          $       1,615  $       1,789
  Service and repair fees - net                        2,807          2,653
  Service and repair fees - related parties -
   net                                                    27             55
  Management and other fees - net                      3,308          2,380
  Management and other fees - related medical
   practices - net                                     1,571          1,142
                                               -------------  -------------
    Total Revenues - Net                               9,328          8,019
                                               -------------  -------------

COSTS AND EXPENSES
  Costs related to product sales                       1,171          1,368
  Costs related to service and repair fees               868            700
  Costs related to service and repair fees -
   related parties                                         9             15
  Costs related to management and other fees           1,887          1,707
  Costs related to management and other fees -
   related medical practices                             901            633
  Research and development                               293            153
  Selling, general and administrative                  1,995          1,745
  Provision for bad debts                                310            255
                                               -------------  -------------
    Total Costs and Expenses                           7,434          6,576
                                               -------------  -------------

Income From Operations                                 1,894          1,443

Interest Expense                                        (124)          (137)
Investment Income                                         64             58
Other Expense                                             (1)            (1)
Provision for Income Taxes                               (21)             -
                                               -------------  -------------

Net Income                                             1,812          1,363
Net Income - Non Controlling Interests                   276              -
                                               -------------  -------------
Net Income - Controlling Interests             $       1,536  $       1,363
                                               =============  =============
Net Income Available to Common Stockholders    $       1,432  $       1,262
                                               =============  =============
Net Income Available to Class A Non-Voting
 Preferred Stockholders                        $          78  $          75
                                               =============  =============
Net Income Available to Class C Common
 Stockholders                                  $          26  $          26
                                               =============  =============
Basic Net Income Per Common Share              $        0.25  $        0.25
                                               =============  =============
Diluted Net Income Per Common Share            $        0.24  $        0.24
                                               =============  =============
Basic and Diluted Income Per Share-Common C    $        0.07  $        0.07
                                               =============  =============
Weighted Average Basic Shares Outstanding          5,728,528      5,149,499
                                               =============  =============
Weighted Average Diluted Shares Outstanding        5,856,032      5,277,003
                                               =============  =============

                     FONAR CORPORATION AND SUBSIDIARIES
          CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
                   (000's OMITTED, except per share data)

                                                 FOR THE SIX MONTHS ENDED
                                                       DECEMBER 31,
                                               ----------------------------
                                                    2011           2010
                                               -------------  -------------
REVENUES
  Product sales - net                          $       3,391  $       4,448
  Service and repair fees - net                        5,712          5,342
  Service and repair fees - related parties -
   net                                                    55            110
  Management and other fees - net                      6,637          4,469
  Management and other fees - related medical
   practices - net                                     3,141          2,335
                                               -------------  -------------
    Total Revenues - Net                              18,936         16,704
                                               -------------  -------------

COSTS AND EXPENSES
  Costs related to product sales                       2,646          3,873
  Costs related to service and repair fees             1,682          1,366
  Costs related to service and repair fees -
   related parties                                        16             28
  Costs related to management and other fees           4,072          3,021
  Costs related to management and other fees -
   related medical practices                           1,720          1,372
  Research and development                               622            607
  Selling, general and administrative                  4,037          4,128
  Provision for bad debts                                485            431
                                               -------------  -------------
    Total Costs and Expenses                          15,280         14,826
                                               -------------  -------------

Income From Operations                                 3,656          1,878

Interest Expense                                        (231)          (231)
Interest Expense - Related Party                           -             (4)
Investment Income                                        126             96
Interest Income - Related Party                            -              1
Other Income                                              55              8
Provision for Income Taxes                               (21)             -
                                               -------------  -------------
Net Income                                             3,585          1,748
Net Income - Non Controlling Interests                   535              -
                                               -------------  -------------
Net Income - Controlling Interests             $       3,050  $       1,748
                                               =============  =============
Net Income Available to Common Stockholders    $       2,842  $       1,618
                                               =============  =============
Net Income Available to Class A Non-voting
 Preferred Stockholders                        $         155  $          97
                                               =============  =============
Net Income Available to Class C Common
 Stockholders                                  $          53  $          33
                                               =============  =============
Basic Net Income Per Common Share              $        0.50  $        0.32
                                               =============  =============
Diluted Net Income Per Common Share            $        0.49  $        0.31
                                               =============  =============
Basic and Diluted Income Per Share-Common C    $        0.14  $        0.09
                                               =============  =============
Weighted Average Basic Shares Outstanding          5,698,645      5,080,872
                                               =============  =============
Weighted Average Diluted Shares Outstanding        5,826,149      5,208,376
                                               =============  =============

Contact:
Daniel Culver
Director of Communications
FONAR Corporation
Tel: 631-694-2929
Fax: 631-390-1709
http://www.fonar.com

GlobalWise (GWIV) Completes Acquisition of Intellinetics

COLUMBUS, OH — (Marketwire) — 02/14/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) today announces the completion of its acquisition of Intellinetics, Inc. (www.Intellinetics.com).

Intellinetics, Inc., now a wholly owned subsidiary of GlobalWise Investments, is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. Leveraging its cloud-based computing software, GlobalWise Investments is poised to capture a significant market share of the burgeoning ECM industry.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization and automated content management with an open and service-oriented architecture using Web services. The Company provides strategies, tactics and technologies to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full-time employee.

The Company’s ECM service is delivered to customers via five unique delivery models that cover the full spectrum of business needs: Cloud/SaaS (Software as a Service); Hardware Vendor Integrated Service; Software Vendor Integrated Service; Premise (Client-Server); and Hybrid (Premise & Cloud/SaaS). This diversity provides advanced security and privacy features with an on-demand structure for businesses in the large, underserved Tier 3 and Tier 4 markets.

William J. “BJ” Santiago, President and CEO of GlobalWise Investments, stated, “IBM Market Insights predicts adoption of cloud computing to continue growing at a compound annual growth rate of 26% until 2013. Through its acquisition of Intellinetics, GlobalWise Investments is well positioned to secure a strong foothold in this rapidly growing ECM industry.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

VistaGen (VSTA) Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates

SOUTH SAN FRANCISCO, CA — (Marketwire) — 02/14/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has identified its initial Top 10 drug rescue candidates and plans to launch two formal drug rescue programs by the end of next quarter.

VistaGen’s goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development.

“We are now at an advanced stage in our business model,” said Shawn Singh, VistaGen’s Chief Executive Officer. “After more than a decade of focused investment in pluripotent stem cell research and development, we are now at the threshold where game-changing science becomes therapeutically relevant to patients and commercially relevant to our shareholders. We have positioned our company and our stem cell technology platform to pursue multiple large market opportunities. We plan to launch two drug rescue programs by the end of the next quarter.”

Over the past year, VistaGen, working with its network of strategic partners, identified over 525 once-promising new drug candidates that meet the Company’s preliminary screening criteria for heart toxicity-focused drug rescue using CardioSafe 3D™, its human heart cell-based bioassay system. After internally narrowing the field to 35 compounds, VistaGen, working together with its external drug rescue advisors, including former senior pharmaceutical industry executives with drug safety and medicinal chemistry expertise, analyzed and carefully narrowed the group of 35 to the current Top 10.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen’s oral small molecule prodrug candidate, AV-101 (4-Cl-KYN), is in Phase 1b development for treatment of neuropathic pain. Unlike other NMDA receptor antagonists developed previously, AV-101 readily crosses the blood-brain barrier and is then efficiently converted into 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and specific glycineB site antagonists currently known, and has been shown to reduce seizures and excitotoxic neuronal death. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101. The Company anticipates pursuing Phase 2 development for neuropathic pain and other neurological indications, including depression, epilepsy, and/or Parkinson’s disease in the event it receives additional non-dilutive development grant funding from the NIH or private foundations.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen’s stem cell technology-based drug rescue activities, ongoing AV-101 clinical studies, its ability to enter into drug rescue collaborations and/or licensing arrangements with respect to one or more drug rescue variants, risks and uncertainties relating to the availability of substantial additional capital to support VistaGen’s research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Universal Security Instruments (UUU) Reports Third-Quarter Results

UTStarcom (UTSI) Wins Two China Telecom Provincial IPTV Network Expansion Contracts

SeraCare (SRLS) Reports 9 Percent Revenue Growth in First Quarter Fiscal Year 2012

A123 Systems (AONE) to Supply Six Battery Energy Storage Solutions to Northern Powergrid

WALTHAM, Mass., Feb. 10, 2012 (GLOBE NEWSWIRE) — A123 Systems (Nasdaq:AONE), a developer and manufacturer of advanced Nanophosphate® lithium ion batteries and systems, today announced that it will supply six Grid Battery Systems™ (GBSs) to Northern Powergrid, an electricity distribution network operator that delivers power to more than 3.8 million customers in the U.K. The GBSs will be designed for peak-load shifting and to manage fluctuations in voltage on the U.K.’s power grid. Expected to be operational by the end of 2012, the systems will be deployed as part of the Customer-Led Network Revolution (CLNR), the U.K.’s largest smart grid project funded through the Office of the Gas and Electricity Markets’ (Ofgem) Low Carbon Networks Fund.

“The CLNR will evaluate a number of innovative network technologies to accommodate increasing quantities of low-carbon loads and renewable generation necessary to meet the U.K.’s climate change goals. One aspect of this multifaceted project is to determine how the use of storage technology may reduce peak loading on our network and thereby offset the need for network reinforcement,” said Jim Cardwell, head of regulation and strategy at Northern Powergrid. “A123’s battery energy storage systems will showcase how such technology can be part of the U.K.’s low-carbon future.”

A123’s GBS storage systems, which include the company’s Smart Grid Domain Controller™, are designed to provide Northern Powergrid with robust solutions to more efficiently manage voltage regulation requirements to help maintain grid stability and power quality as more clean energy resources are added. The six GBSs that A123 will supply to Northern Powergrid include a 2.5MW system, two 100kW systems and three 50kW systems. Each will be designed to maintain these power capabilities for up to two hours, adding flexibility to the distribution network and helping to provide consistent delivery of reliable power to customers.

“Grid operators around the world are faced with a variety of technical hurdles when trying to add significant renewable capacity. In the U.K., distribution networks often have limitations that make adding high concentrations of wind and solar difficult,” said Robert Johnson, vice president of the Energy Solutions Group at A123. “Battery energy storage can overcome these challenges by efficiently managing the voltage levels of the power network, and we look forward to working with Northern Powergrid on the CLNR smart grid project, which we view as an excellent opportunity for A123 to showcase the versatility and performance of our GBS solutions.”

About A123 Systems

A123 Systems, Inc. (Nasdaq:AONE) is a leading developer and manufacturer of advanced lithium-ion batteries and energy storage systems for transportation, electric grid and commercial applications. The company’s proprietary Nanophosphate® technology is built on novel nanoscale materials initially developed at the Massachusetts Institute of Technology and is designed to deliver high power and energy density, increased safety and extended life. A123 leverages breakthrough technology, high-quality manufacturing and expert systems integration capabilities to deliver innovative solutions that enable customers to bring next-generation products to market. For additional information, please visit www.a123systems.com.

The A123 Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6600

Safe Harbor Disclosure

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: changes or delays in Northern Power Grid’s development and implementation of the GBS solutions in connection with the Customer-Led Network Revolution project, delays or inability of the GBS solutions or the Customer-Led Network Revolution project to meet their intended goals and objectives, the ability of A123’s GBS storage systems to manage voltage regulation requirements of the power network and to address Northern Power Grid’s needs in connection with the Customer-Led Network Revolution project , delays in customer and market demand for Northern Power Grid’s products and services, delays in the implementation of A123’s GBS solutions , delays in the development, production and delivery of A123’s products and solutions, adverse economic conditions in general and adverse economic conditions specifically affecting the markets and geographies in which A123 and Northern Power Grid operate and other risks detailed in A123 Systems’ quarterly report on Form 10-Q for the quarter ended September 30, 2011 and other publicly available filings with the Securities and Exchange Commission. All forward-looking statements reflect A123’s expectations only as of the date of this release and should not be relied upon as reflecting A123’s views, expectations or beliefs at any date subsequent to the date of this release.

CONTACT: A123 Systems PR Contact:
         A123 Systems
         Dan Borgasano
         617-972-3471
         dborgasano@a123systems.com

         Edelman
         Courtney Kessler
         212-277-3720
         courtney.kessler@edelman.com

         A123 Systems IR Contact:
         ICR, LLC
         Garo Toomajanian
         617-972-3450
         ir@a123systems.com

Tandy Brands (TBAC) Reports Fiscal 2012 Second Quarter Earnings Results

DALLAS, Feb. 10, 2012 (GLOBE NEWSWIRE) — Tandy Brands Accessories, Inc. (Nasdaq:TBAC) today reported financial results for its second quarter and six-month periods ended December 31, 2011.

Net sales for the second quarter were $45.4 million, an increase of $2.5 million versus the prior year second quarter. Gifts segment net sales of $22.7 million increased by $6.0 million over the prior year period due to increased holiday shipments as a result of organic growth from the Company’s totes^® license and new sales from the Eddie Bauer^® license. Net sales in the accessories segment were $22.7 million for the second quarter, a decline of $3.5 million from fiscal 2011. The decline reported in the Accessories segment net sales was a result of lower sales in exited product categories and lower levels of replenishment orders by the Company’s largest customer.

“We are pleased to see our initiatives drive positive results,” said Rod McGeachy, President and Chief Executive Officer of Tandy Brands. “We delivered profitable growth and realized the benefits from recent cost savings initiatives to improve our bottom line.”

Second quarter fiscal 2012 gross margin as a percentage of net sales was 30.9 percent, compared to 33.2 percent in the second quarter of fiscal 2011. Although accessories segment gross margins improved, overall gross margins declined due to a higher mix towards customer-direct shipments, higher customer deductions for holiday markdowns, and increased sales to higher volume, lower margin customers in the gift segment.

Total selling, general and administrative (SG&A) expense for the fiscal 2012 second quarter improved by $2.3 million over the prior year period. This 18 percent improvement was due to savings initiatives in labor, facilities costs, and professional services.

For the second quarter, the Company reported net income of $2.7 million, or $0.39 per diluted share, compared to net income of $0.7 million, or $0.10 per diluted share, in the prior year.

Six-Month Results

Net sales for the six-month period ended December 31, 2011 were $72.2 million compared to net sales of $72.1 million reported in the prior-year period. An increase in net sales of the gifts segment was due to an increase in business under the totes^® license and new sales under the Eddie Bauer^® license. This was offset by the planned exit from non-profitable product categories initiated at the end of the prior fiscal year in the accessories segment.

Gross margin as a percentage of net sales was 32.1% in the first half of fiscal 2012, down from 33.9% in the first half of fiscal 2011. The decline was due to a change in sales mix in the gifts segment including a higher mix towards customer-direct shipments, higher freight and material costs, and increased sales to higher volume, lower margin customers.

Total SG&A expense for the six-month period decreased $5.0 million to $19.4 million in fiscal 2012 due to decreases in labor, facilities costs, and professional services.

The Company reported net income of $1.7 million, or $0.23 per diluted share, compared to a net loss of $2.0 million, or a loss of $0.28 per diluted share, in the prior-year period.

Financial Position

Net cash provided by operating activities was $17.7 million higher than the first half of fiscal 2011 due to a $3.8 million improvement in adjusted EBITDA, faster collections on receivables, lower inventory levels, and lower funding of accounts payable and accrued expenses. Inventories were reduced by $5.7 million to $32.7 million as of December 31, 2011, due to lower levels of inventory carried during the current year. Accounts receivable was reduced by $8.7 million to $16.4 million on flat net sales due to faster collection of receivables with the Company’s largest customer.

As of December 31, 2011 the Company reported net working capital of $25.1 million. Current liabilities of $29.0 million as of December 31, 2011 decreased $6.4 million from December 31, 2010 primarily driven by a $6.2 million reduction in outstanding debt.

“We are pleased by our improvement in cash flow from operations,” said McGeachy. “We will continue to focus on accelerating our cash cycle and making prudent investment decisions with our cash. We are performing well against our debt covenants and successfully reducing overall debt. As of February 9, 2012 our loan balance was $8.5 million compared to $13.8 million during the same period a year ago.”

New Licensing Agreements

In the third quarter of fiscal 2012, the Company signed new licenses with Sperry Top-Sider^® and Arnold Palmer Enterprises (APE). Both of these licenses are expected to impact results in the Company’s accessories segment beginning in calendar 2013.

Under the agreement with Sperry Top-Sider^®, Tandy Brands will have the rights to leverage its expertise in belts, shoulder bags, and small leather goods for both men and women. Sperry Top-Sider^® products will be distributed through premium department stores and specialty retailers throughout the United States and Canada, Sperry Top-Sider’s own retail stores, and on sperrytopsider.com.

“We are excited to partner with Sperry Top-Sider, a brand recognized as an icon of American style for more than 75 years with distinct equities which we will leverage to develop a compelling product offering,” said McGeachy.

Under the agreement with APE, Tandy Brands will have the rights to leverage its expertise in golf belts. Incremental distribution is expected in green grass golf shops, off-course golf specialty stores, department stores, corporate shops and e-commerce shops.

“We are excited to be partnering with Arnold Palmer, one of the most successful names in the game of golf. Arnold Palmer’s popularity is legendary and his name provides unquestioned authenticity to our products,” said McGeachy.

“It is a key strategic imperative that we build our branded portfolio. The licenses we added last year (e.g. Wolverine^®, Bone Collector^®, Eddie Bauer^®, and Haggar^®) delivered meaningful, profitable growth in fiscal 2012. Furthermore, the new licenses we added this year (e.g. Miss Me^®, The Sharper Image^®, Elie Tahari^®, Sperry^®, and Arnold Palmer^®) make our growth pipeline even stronger. We expect all of these nationally recognized consumer brands to increase future net sales, improve gross margin percentage, reduce our customer concentration risk and improve our mix of lower-margin private label business,” said McGeachy.

Outlook

“Although diminishing, our customer concentration risk remains. Nonetheless, we expect to see continued growth in our gifts segment and from the new licenses we’ve added to our portfolio,” commented McGeachy.

“We are focused on restoring shareholder value through improving operational efficiency, growing volume in our key product categories, and adding new licenses to our portfolio,” said McGeachy.

About Tandy Brands

Tandy Brands is a leading designer and marketer of branded men’s, women’s and children’s accessories, including belts, gifts and small leather goods. Merchandise is marketed under various national as well as private brand names through all major retail distribution channels.

Safe Harbor Language

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company has based these forward-looking statements on its current expectations about future events, estimates and projections about the industry in which it operates. Forward-looking statements are not guarantees of future performance. Actual results may differ materially from those suggested by these forward-looking statements as a result of a number of known and unknown risks and uncertainties that are difficult to predict, including, without limitation, general economic and business conditions, competition in the accessories and gifts markets, acceptance of the Company’s product offerings and designs, issues relating to distribution, the termination or non-renewal of any material licenses, the Company’s ability to maintain proper inventory levels, and a significant decrease in business from or loss of any major customers or programs. Those and other risks are more fully described in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements included in this release are made only as of the date hereof. Except as required under federal securities laws and the rules and regulations of the United States Securities and Exchange Commission, the Company does not undertake, and specifically declines, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this release, whether as a result of new information, future events, changes in assumptions, or otherwise.

CONTACT: Tandy Brands Accessories, Inc.
         Rod McGeachy
         President and Chief Executive Officer
         214-519-5200

         Investor Relations
         Chuck Talley
         Chief Accounting Officer
         214-519-5200

VistaGen Therapeutics (VSTA) Increases Its Drug Rescue Opportunities With Right-of-First-Offer Agreement With Cato BioVentures and Cato Research

SOUTH SAN FRANCISCO, CA — (Marketwire) — 02/08/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has signed a strategic drug rescue agreement with Cato BioVentures and Cato Research.

The companies will join forces to identify, evaluate, rescue and develop once-promising new, small-molecule drug candidates discontinued in late-stage preclinical development by pharmaceutical developers due to heart or liver toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits.

Shawn Singh, VistaGen’s Chief Executive Officer, stated, “Over the past 25 years, Dr. Allen Cato and Lynda Sutton have established Cato Research as a highly successful CRO with unique and long-standing relationships within a broad and diverse network of pharmaceutical companies and regulatory agencies around the world. This new agreement is a logical extension of our long-term relationship with both Cato BioVentures and Cato Research. It tightly aligns our stem cell technology-based drug rescue interests with Cato’s CRO growth goals and venture investment objectives. We believe the market demand for effective late-stage preclinical candidates with safety data generated with human heart cells and/or liver cells is strong and increasing. This relationship is yet another key component in our drug rescue ecosystem.”

Under the new agreement, when either Cato BioVentures or Cato Research first becomes aware of a new drug candidate meeting VistaGen’s drug rescue selection criteria, it will approach VistaGen with information about the candidate before any other organization. The expanded relationship is expected to provide VistaGen with potential drug rescue opportunities from within Cato’s broad CRO service and venture capital networks. If VistaGen rescues (generates a new chemical variant of) a drug rescue candidate presented by Cato Research or Cato BioVentures, VistaGen will discuss prospective CRO service opportunities for the new chemical entity with Cato Research before contacting any other CRO.

“By applying the power of human pluripotent stem cell technology, we believe VistaGen is transforming drug development. Its Human Clinical Trial in a Test Tube™ platform puts clinically relevant human heart and liver biology at the front end of the development process, long before human studies. We are pleased to join VistaGen’s efforts to identify and develop new drug candidates faster and less expensively through the use of its stem cell technology platform,” stated Allen Cato, M.D., Ph.D., co-founder and Chief Executive Officer of Cato Research.

About Cato Research and Cato BioVentures
Cato Research is a full-service contract research and development organization (CRO) with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics and medical devices to the people who need them. Cato BioVentures is the venture capital affiliate of Cato Research and one of VistaGen’s largest institutional shareholders. For nearly 25 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development and commercialization programs.

About VistaGen Therapeutics
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during preclinical development due to heart or liver toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen’s small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen plans to initiate Phase 2 clinical development of AV-101 in the fourth quarter of 2012. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson’s disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of VistaGen’s ongoing clinical studies, including the safety and efficacy of its drug candidate, AV-101, the failure of future drug rescue programs related to VistaGen’s stem cell technology-based Human Clinical Trial in a Test Tube™ platform, its ability to enter into drug rescue collaborations, risks and uncertainties relating to the availability of substantial additional capital to support VistaGen’s research, development and commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variants identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Sangamo BioSciences (SGMO) Reports Fourth Quarter and Full Year 2011 Financial Results

Lucas Energy (LEI) Announces Completion of Hagen Ranch No.4H Well

HOUSTON, Feb. 8, 2012 (GLOBE NEWSWIRE) — Lucas Energy, Inc. (NYSE Amex:LEI), an independent oil and gas company (the “Company” or “Lucas”), today announced that the Company has completed the Hagen Ranch No.4H well in Gonzales County, Texas as a flowing horizontal oil well in the Austin Chalk formation. The official 24 hour test that will be reported to the regulatory agency is 475 BOPD (barrels of oil per day, 232 MCFPD (thousands of cubic feet) of gas, and 103 BWPD (barrels of water per day – load water or drilling water, not formation water) with 419 psig (pounds per square inch) of FTP (flowing tubing pressure) on a 20/64″ choke. Lucas has approximately a 25% working interest in this well.

Further testing indicated that the well is capable of producing 846 BOPD, 422 MCFPD, and 264 BLWPD (load water) at 283 psig FTP on a 36/64″ choke. This choke size is slightly greater than a ½” pipe, or approximately 60% of the full opening choke size. Indications are that the Hagen Ranch No.4H well may have a greater capacity curing the initial production period. Future production rates will be determined by technical information, safety, tank capacity, and other factors. At some time in the future, the well may be put on artificial lift. Specifically a pumping unit may be added.

William A. Sawyer, President and Chief Executive Officer of the Company, said, “The drilling and completion of the Hagen Ranch No.4H well opens a new chapter in the company history book.” For more information on this and other activities of the Company, visit the Lucas Energy web site at www.lucasenergy.com.

Company Website: www.lucasenergy.com

Forward-Looking Statement

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Act”) and Section 21E of the Securities Act of 1934, as amended (the “Exchange Act”). In particular, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements and are subject to the safe harbor created by these Acts. Any statements made in this news release about an action, projection, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Statements regarding future drilling and production are subject to all of the risks and uncertainties normally incident to the exploration and development of oil and gas. These risks include, but are not limited to, completion risk, dry hole risk, price volatility, reserve estimation risk, regulatory risk, potential inability to secure oilfield service risk as well as general economic risks and uncertainties, as disclosed in the Company’s SEC filings including its Form 10-K and Form 10-Q’s. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company’s SEC filings are available at http://www.sec.gov.

The Lucas Energy logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4192

CONTACT: Andrew Lai, CFO
         alai@lucasenergy.com
         (713) 528-1881

         Michael Brette J.D., Advisor
         mikebrette@gmail.com
         (951) 236-8473

RAM Energy Resources, Inc. (RAM) Announces Closing of $550 Million Recapitalization

NovaBay Pharmaceuticals (NBY) to Present at the 14th Annual BIO CEO & Investor Conference

EMERYVILLE, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) — NovaBay^® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide^® compounds for the local non-systemic treatment and prevention of infections, today announced that Ron Najafi, Chief Executive Officer, will present at the 14^th Annual BIO CEO & Investor Conference in New York, NY, held February 13-14, 2011, at the Waldorf-Astoria Hotel.

Dr. Najafi and Tom Paulson, Chief Financial Officer, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.

Event	14th Annual BIO CEO & Investor Conference
Date	Tuesday, February 14, 2012
Time	10:00am ET
Place	The Waldorf-Astoria Hotel (Duke of Windsor, 4th floor)

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.

NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 Gel formulation for the highly contagious skin infection, impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for viral conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422. In hospital infections, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase®, the only pure hypochlorous acid solution which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit: www.novabaypharma.com.

CONTACT: Investors:
         NovaBay Pharmaceuticals, Inc.
         Thomas J. Paulson
         Chief Financial Officer
         510-899-8809
         tjpaulson@NovaBaypharma.com

         Investors and Media:
         The Ruth Group

         Joshua Drumm, PhD (Investors)
         (646) 536-7006
         jdrumm@theruthgroup.com

         Victoria Aguiar (Media)
         (646) 536-7013
         vaguiar@theruthgroup.com

Innodata (INOD) Reports Fourth Quarter and Fiscal Year 2011 Results

INNODATA ISOGEN, INC. (NASDAQ: INOD) today reported results for the fourth quarter and the 12 months ended December 31, 2011.

• Total revenue was a record $23.7 million in the fourth quarter of 2011, a sequential increase of 23% from $19.2 million in the third quarter of 2011, and a 59% increase from $14.9 million in the fourth quarter of 2010. The increase is primarily attributable to higher revenue from eBook-related services that the Company performs for one of its larger clients and to revenue from analytics services that the Company performs for a major accounting firm.
• Net income for the fourth quarter of 2011 was $2.3 million, or $0.09 per diluted share, compared to net income of $1.4 million, or $0.06 per diluted share, in the third quarter of 2011, and net income of $1.2 million, or $0.05 per diluted share, in the fourth quarter of 2010. The increase in net income is primarily attributable to higher revenue and to an increase in gross margins from 33% in the third quarter of 2011 and 22% in the fourth quarter of 2010 to 36% in the fourth quarter of 2011.
• For the 12 months ended December 31, 2011, total revenue was $73.9 million, a 20% increase from $61.5 million in 2010. Net earnings improved significantly, from a net loss of $0.7 million, or ($0.03) per diluted share, in 2010, to net earnings of $4.5 million, or $0.18 per diluted share, in 2011. The growth in net earnings is primarily attributable to higher revenue and to an increase in gross margins from 23% in 2010 to 32% in 2011.
• Cash and cash equivalents and short-term investments totaled $17.2 million as of December 31, 2011, a decline of $7.0 million from $24.2 million as of September 30, 2011. The reduction is primarily on account of an $8.8 million increase in accounts receivable from $12.9 million as of September 30, 2011 to $21.7 million as of December 31, 2011 and approximately $2.5 million in investments made during the quarter for establishing two new delivery centers in Asia, and continuing investment in the Company’s recently-launched Innodata Advanced Data Solutions (IADS) segment. A significant portion of the increase in accounts receivable as of December 31, 2011 was from one of our large customers because of a process delay.

“In 2011, we succeeded at growing revenue by 20% and turning a 2010 pre-tax loss of $1.2 million to 2011 pre-tax earnings of $5.3 million, all the while making an investment of $2.7 million in operating expenses and $2 million in capital expenditures in our IADS division,” stated Jack Abuhoff, the Company’s Chairman and CEO. “Our IADS investment has enabled us to build a platform and service capability to provide high quality advanced data analytics to healthcare, financial, and insurance sectors for risk management and related business operations. We expect that IADS will begin contributing to revenue during the first half of 2012.”

Abuhoff concluded, “Our business in 2012 is off to a good start. We’re anticipating revenue for the first quarter of 2012 to be approximately $21.0 million.”

Timing of Conference Call with Q&A

Innodata will conduct an earnings conference call, including a question and answer period, at 11:00 AM eastern time today. You can participate in this call by dialing the following call-in numbers:

The call-in numbers for the conference call are:

1-800-723-6575 (Domestic)

1-785-830-1997 (International)

1-888-203-1112 (Domestic Replay)

1-719-457-0820 (International Replay)

Pass code on both: 7914822

Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of www.innodata.com. Please note that the Webcast feature will be in listen-only mode.

Call-in or Webcast replay will be available for 30 days following the conference call.

Innodata (NASDAQ: INOD) is a leading provider of business process, technology and consulting services, as well as products and solutions, that help our valued clients create, manage, use and distribute digital information. Propelled by a culture of quality, service and innovation, we have developed a client base that includes many of the world’s preeminent media, publishing and information services companies, as well as leading enterprises in information-intensive industries such as aerospace, defense, financial services, government, healthcare, high technology, insurance, intelligence, manufacturing and law.

Recent honors include EContent Magazine’s EContent 100, KMWorld Magazine’s 100 Companies That Matter in Knowledge Management, the International Association of Outsourcing Professionals’ (IAOP) Global Outsourcing Top 100, D&B India’s Leading ITeS and BPO Companies and the Black Book of Outsourcing’s Top List of Leading Outsourcing Providers to the Printing and Publishing Business.

Headquartered in the New York metro area, Innodata has offices and operations in the United States, the United Kingdom, Israel, India, Sri Lanka, and the Philippines.

This release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The words “project,” “head start,” “believe,” “expect,” “should,” “anticipate,” “indicate,” “point to,” “forecast,” “likely”, “optimistic” and other similar expressions generally identify forward-looking statements, which speak only as of their dates.

These forward-looking statements are based largely on our current expectations, and are subject to a number of risks and uncertainties, including without limitation, that our Innodata Advanced Data Solutions segment has not reported any revenues to date and is subject to the risks and uncertainties of early-stage companies; the primarily at-will nature of the contracts between our Content Services segment and its customers and the ability of customers to reduce, delay or cancel projects; continuing Content Services revenue concentration in a limited number of customers; continuing Content Services reliance on project-based work; inability to replace projects that are completed, cancelled or reduced; depressed market conditions; changes in external market factors; the ability and willingness of our customers and prospective customers to execute business plans which give rise to requirements for digital content and professional services in knowledge processing; difficulty in integrating and deriving synergies from acquisitions, joint venture and strategic investments; potential undiscovered liabilities of companies that we acquire; changes in our business or growth strategy; the emergence of new or growing competitors; various other competitive and technological factors; and other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.

Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this release will occur.

AdCare Health Systems (ADK) to Present at the UBS 22nd Annual Global Healthcare Services Conference on February 7, 2012

SPRINGFIELD, OH — (Marketwire) — 02/06/12 — AdCare Health Systems, Inc. (NYSE Amex: ADK), a nursing home and assisted living company, has been invited to present at the UBS 22nd Annual Global Healthcare Services Conference. The conference will be held at the Grand Hyatt New York in New York City on February 7-8, 2012.

AdCare CEO Boyd Gentry, and its chief acquisition officer, Chris Brogdon, are scheduled to present on Tuesday, February 7, 2012 at 8:00 a.m. Eastern time, with one-on-one meetings held throughout the day. AdCare management will discuss the emerging opportunities in the highly fragmented health care segments of senior assisted living and elderly nursing care.

The company will also talk about the progress of AdCare’s M&A program designed to build upon its strong reputation for operational efficiency and high-quality living environments. With the recent acquisition of a skilled nursing and assisted living community in Ohio, plus 24 additional skilled nursing centers AdCare expects to close in the first quarter of 2012 and the Abington Place skilled nursing facility in Q2 2012, the company expects its annualized revenue run-rate to exceed $355 million, which would represent an increase of 570% over revenues in 2010.

The presentation will be broadcast simultaneously and available for replay at www.ibb.ubs.com/Conferences and the investor relations section of the company’s website at www.adcarehealth.com.

For more information about the conference or to schedule a one-on-one meeting with AdCare management, please contact your UBS representative or visit the conference website at www.ibb.ubs.com.

About UBS
Headquartered in Zurich and Basel, UBS is a global firm providing financial services to private, corporate and institutional clients. UBS is present in all major financial centers and has offices in over 50 countries. UBS employs more than 65,000 people around the world. UBS’s historical roots stretch back more than a century. For more information, visit www.ubs.com.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) is a recognized innovator in senior living and health care facility management. AdCare develops, owns and manages assisted living facilities, nursing homes and retirement communities. Since its inception in 1988, AdCare’s mission has been to provide the highest quality of healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Important Cautions Regarding Forward-Looking Statements
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such statements can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “intends,” “anticipates” and variations of such words or similar expressions, but their absence does not mean that the statement is not forward-looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the company’s expected annualized revenue run-rate and statements regarding the expected closing of transactions. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of AdCare which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by AdCare with the Securities and Exchange Commission and include, among others, AdCare’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements. Except where required by law, AdCare undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Company Contacts
Boyd Gentry, CEO
Chris Brogdon, Vice Chairman & CAO
David A. Tenwick, Chairman of Board
AdCare Health Systems, Inc.
Tel (937) 964-8974

Investor Relations
Ron Both or Geoffrey Plank
Liolios Group, Inc.
Tel (949) 574-3860

Misonix, Inc. (MSON) to Report Second Quarter Fiscal 2012 Financial Results on Wednesday, February 8, 2012

Orexigen (OREX) Announces Agreement From the FDA on a Special Protocol Assessment for the Contrave® Outcomes Trial

Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed’s (ENMD) Board of Directors

Cybex (CYBI) Reaches Settlement in Barnhard Product Liability Suit

Cybex International, Inc. (NASDAQ: CYBI), a leading manufacturer of premium exercise equipment, announced today that it has reached a settlement in the product liability litigation, Barnhard v. Cybex International, Inc. Pursuant to the settlement, Cybex will pay to the plaintiff, net of insurance, approximately $19,500,000, of which approximately $18,500,000 will be paid at the consummation of the settlement with the balance paid over seven years. As part of the settlement, Cybex will be released of all further liability with respect to the litigation, which will be dismissed with prejudice. Cybex will satisfy its cash obligation through available cash, its existing line of credit and additional financing, which it is in the process of arranging with its principal bank.

The settlement is subject to standard closing conditions, including the execution of a definitive settlement agreement by Cybex, the plaintiff and the third party defendant. Cybex anticipates that all conditions will be satisfied and funds disbursed within the next 30 days.

As previously reported, Cybex currently is subject to possible de-listing from the Nasdaq Stock Market due to its failure to comply with the Nasdaq requirements for a minimum stockholders’ equity of $10,000,000, a minimum bid price for its common stock of $1.00 per share and a minimum market value of publicly held shares of $5,000,000. Cybex is analyzing the impact the settlement will have on its financial statements. However, looking forward, Cybex is confident that, once the settlement is reflected in the Company’s financial statements, its stockholders’ equity will exceed the $10,000,000 minimum required by Nasdaq.

Cybex Chairman and CEO John Aglialoro states, “The positive financial impact of this settlement will be reflected in our Q4 results. As we move past this lawsuit, Cybex remains a healthy business and a leader in the fitness industry. We are confident of our future as we move forward with our Cybex team.”

Cybex anticipates announcing 2011 results on or around February 16, 2012.

About Cybex

Cybex International, Inc. is a leading manufacturer of premium exercise equipment primarily for commercial use. The Cybex product line, including a full range of strength and cardio training machines, is designed using exercise science to reflect the natural movement of the human body. Led by the Cybex Research Institute, Cybex fitness equipment is engineered to produce optimal results for users from the first-time exerciser to the professional athlete. Products are available for a wide range of facilities, from commercial health clubs to home gyms, and are sold in more than 85 countries worldwide. For more information on Cybex and its product lines, visit the Company’s website at www.cybexintl.com.

This news release may contain forward-looking statements. There are a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made above. These include, but are not limited to, the resolution of litigation involving the Company, the ability of the Company to comply with the terms of its credit facilities, competitive factors, technological and product developments, market demand, and economic conditions. Further information on these and other factors which could affect the Company’s financial results can be found in the Company’s previously filed Report on Form 10-K for the year ended December 31, 2010, its Reports on Form 10-Q, its Current Reports on Form 8-K, and its proxy statement dated April 14, 2011.